Accepted Manuscript

Global analysis of metastatic breast cancer policy gaps and advocacy efforts across the patient journey

Maia Thrift-Perry, Anna Cabanes, Fatima Cardoso, Katherine Moose Hunt, Tauane Araújo Cruz, Kyra Faircloth

THE BREAST

As an invariant was a few as a few a

PII: S0960-9776(18)30109-7

DOI: 10.1016/j.breast.2018.06.005

Reference: YBRST 2764

To appear in: The Breast

Received Date: 30 April 2018 Revised Date: 5 June 2018 Accepted Date: 8 June 2018

Please cite this article as: Thrift-Perry M, Cabanes A, Cardoso F, Hunt KM, Cruz TauaneAraú, Faircloth K, Global analysis of metastatic breast cancer policy gaps and advocacy efforts across the patient journey, *The Breast* (2018), doi: 10.1016/j.breast.2018.06.005.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Global analysis of metastatic breast cancer policy gaps and advocacy efforts across the patient journey

Maia Thrift-Perry M.P.H.^a, Anna Cabanes Ph.D., M.P.H.^{b*}, Fatima Cardoso M.D.^{c,d}, Katherine Moose Hunt M.P.A.^b, Tauane Araújo Cruz M.B.A.^b, Kyra Faircloth M.S.^a

* Corresponding author, Susan G. Komen, 5005 LBJ Freeway, Suite 526, Dallas, TX 75244, USA Email address: ACabanes@komen.org(A. Cabanes)

COI:

- M. Thrift-Perry is an employee of Pfizer Inc, receiving a salary and stock.
- K. Faircloth is an employee of Pfizer Inc, receiving a salary and stock.

Dr. Cardoso has disclosed the following financial relationships: Served on advisory board for Pfizer, Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pierre-Fabre, Roche, Sanofi, Seattle Genetics, Teva

Keywords:

Metastatic Breast Cancer; Breast Cancer; National Cancer Control Plan; Policy; Advocacy; Implementation

Funding:

Susan G. Komen and Dr. Fatima Cardoso did not receive any direct funding from Pfizer Inc. for their contributions to this work. The initial research, data analyses and manuscript editorial assistance to the authors was provided by Tim Wilsdon M.S., Artes Haderi M.S. and Rajini Jayasuriya M.S. of Charles River Associates, a consultancy, and was funded by Pfizer Inc.

Acknowledgements:

A special thank you to Tim Wilsdon, Artes Haderi and Rajini Jayasuriya, of Charles River Associates, a consultancy, for research, data interpretation and manuscript editorial assistance, sponsored by Pfizer. We thank all authors who contributed to the manuscript and approved the final version for submission. Finally, to the patients, caregivers, and families who are impacted by this disease. You are the motivation for our work.

Ethical approval:

Ethical approval was not required for this study.

^a International Public Affairs, Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA

^b Global Programs, Susan G. Komen, 5005 LBJ Freeway, Suite 526, Dallas, TX 75244, USA

^c Breast Unit, Champalimaud Clinical Center, Av Brasilia, s/n Lisbon, Lisbon 1400-038, Portugal

^d European School of Oncology, Via Filippo Turati, 29, 20121 Milan, Italy

Download English Version:

https://daneshyari.com/en/article/8776642

Download Persian Version:

https://daneshyari.com/article/8776642

<u>Daneshyari.com</u>